SpringerLink
Log in

Y-box binding protein 1 expression in gastric cancer subtypes and association with cancer neovasculature

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Y-box binding protein 1 (YB-1) expression in cancer cells is closely associated with malignant progression and poor prognosis in various cancers. Recently, we demonstrated that YB-1 expression in cancer cells is an immunomarker for patient prognosis and liver metastasis of gastric cancer (GC), and identified YB-1 as an excellent biomarker of angiogenic and proliferating endothelial cells in cancers. We further explored the expression patterns of YB-1 in gastric vasculature and the relationship with the clinical pathologic characteristics, as well as YB-1 phenotype in cancer cells.

Methods/Patients

Immunohistochemical analysis of YB-1 was performed using 163 surgically resected primary GC specimens.

Results

YB-1 expression in cancer cells significantly differed with respect to Lauren type, JGCA classification, vascular invasion (VI), and microvessel density (MVD) of cancers (P = 0.018, P = 0.002, P < 0.001, and P < 0.001, respectively). No correlation was found between cancer-cell YB-1 expression and TNM stage or lymphatic invasion. However, YB-1 expression in vascular endothelial cells significantly correlated with N stage, M stage, TNM stage, and MVD of cancers (P < 0.001, P = 0.013, P < 0.001, and P < 0.001, respectively). Notably, cases with YB-1 expression in cancer vasculature also demonstrated YB-1 expression in cancer cells (P = 0.040).

Conclusions

YB-1 may promote GC development through its function in both cancer cells and cancer vascular cells, and thus represent a potential biomarker in this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ilson DH. Angiogenesis in gastric cancer: hitting the target? Lancet. 2013. doi:10.1016/S0140-6736(13)61892-9.

    PubMed  Google Scholar 

  2. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2013. doi:10.1016/S0140-6736(13)61719-5.

    Google Scholar 

  3. Razzak M. Targeted therapies: hope for antiangiogenic therapy in advanced gastric cancer. Nature rev Clin oncol. 2013;10(10):548. doi:10.1038/nrclinonc.2013.156.

    Article  Google Scholar 

  4. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays. 2003;25(7):691–8. doi:10.1002/bies.10300.

    Article  CAS  PubMed  Google Scholar 

  5. Takahashi M, Shimajiri S, Izumi H, Hirano G, Kashiwagi E, Yasuniwa Y, et al. Y-box binding protein-1 is a novel molecular target for tumor vessels. Cancer Sci. 2010;101(6):1367–73. doi:10.1111/j.1349-7006.2010.01534.x.

    Article  CAS  PubMed  Google Scholar 

  6. Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry. 2011;76(13):1402–33. doi:10.1134/S0006297911130049.

    CAS  PubMed  Google Scholar 

  7. Lasham A, Print CG, Woolley AG, Dunn SE, Braithwaite AW. YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J. 2013;449(1):11–23. doi:10.1042/BJ20121323.

    Article  CAS  PubMed  Google Scholar 

  8. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J clin oncol. 2009;27(36):6144–51. doi:10.1200/JCO.2008.19.6261.

    Article  CAS  PubMed  Google Scholar 

  9. Wu Y, Yamada S, Izumi H, Li Z, Shimajiri S, Wang KY, et al. Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. J Surg Oncol. 2012;105(7):724–30. doi:10.1002/jso.23030.

    Article  CAS  PubMed  Google Scholar 

  10. Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25(10):1196–208. doi:10.1200/JCO.2006.07.8626.

    Article  CAS  PubMed  Google Scholar 

  11. Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol. 2003;199(2):251–8. doi:10.1002/path.1282.

    Article  CAS  PubMed  Google Scholar 

  12. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res. 2008;68(1):98–105. doi:10.1158/0008-5472.CAN-07-2981.

    Article  CAS  PubMed  Google Scholar 

  13. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric cancer. 2011;14(2):101–12. doi:10.1007/s10120-011-0041-5.

    Article  Google Scholar 

  14. Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res. 1996;56(18):4224–8.

    CAS  PubMed  Google Scholar 

  15. Yasen M, Ka**o K, Kano S, Tobita H, Yamamoto J, Uchiumi T, et al. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res. 2005;11(20):7354–61. doi:10.1158/1078-0432.CCR-05-1027.

    Article  CAS  PubMed  Google Scholar 

  16. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. Vascular grading of angiogenesis: prognostic significance in breast cancer. Br J Cancer. 2000;82(2):339–47. doi:10.1054/bjoc.1999.0924.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84(24):1875–87.

    Article  CAS  PubMed  Google Scholar 

  18. Suzuki S, Dobashi Y, Hatakeyama Y, Tajiri R, Fujimura T, Heldin CH, et al. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-beta phosphorylation, and microvessel density in gastric cancer. BMC Cancer. 2010;10:659. doi:10.1186/1471-2407-10-659.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Kitadai Y. Angiogenesis and lymphangiogenesis of gastric cancer. J oncol. 2010;2010:468725. doi:10.1155/2010/468725.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am j pathol. 2012;181(6):1895–9. doi:10.1016/j.ajpath.2012.08.044.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Lykke-Andersen S, Brodersen DE, Jensen TH. Origins and activities of the eukaryotic exosome. J Cell Sci. 2009;122(Pt 10):1487–94. doi:10.1242/jcs.047399.

    Article  CAS  PubMed  Google Scholar 

  22. Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011;71(15):5346–56. doi:10.1158/0008-5472.CAN-11-0241.

    Article  CAS  PubMed  Google Scholar 

  23. Moser JJ, Fritzler MJ. Cytoplasmic ribonucleoprotein (RNP) bodies and their relationship to GW/P bodies. Int j biochem cell biol. 2010;42(6):828–43. doi:10.1016/j.biocel.2009.11.018.

    Article  CAS  PubMed  Google Scholar 

  24. Furuya M, Yonemitsu Y. Cancer neovascularization and proinflammatory microenvironments. Curr Cancer Drug Target. 2008;8(4):253–65.

    Article  CAS  Google Scholar 

  25. Hammerling GJ, Ganss R. Vascular integration of endothelial progenitors during multistep tumor progression. Cell Cycle. 2006;5(5):509–11.

    Article  PubMed  Google Scholar 

  26. Kosnopfel C, Sinnberg T, Schittek B. Y-box binding protein 1––A prognostic marker and target in tumour therapy. Eur J Cell Biol. 2013. doi:10.1016/j.ejcb.2013.11.007.

    PubMed  Google Scholar 

  27. Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima T, Yamashita J, et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem. 1995;270(47):28316–24.

    Article  CAS  PubMed  Google Scholar 

  28. Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis. 2005;8(1):63–71. doi:10.1007/s10456-005-5208-4.

    Article  CAS  PubMed  Google Scholar 

  29. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002;13(2):143–54.

    Article  CAS  PubMed  Google Scholar 

  30. Lacal PM, Ruffini F, Pagani E, D’Atri S. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol. 2005;27(6):1625–32.

    CAS  PubMed  Google Scholar 

  31. Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo R, Ng TP, et al. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod pathol. 2009;22(2):282–90. doi:10.1038/modpathol.2008.181.

    Article  CAS  PubMed  Google Scholar 

  32. Tsofack SP, Meunier L, Sanchez L, Madore J, Provencher D, Mes-Masson AM, et al. Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis. BMC Cancer. 2013;13:303. doi:10.1186/1471-2407-13-303.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Song YH, Shiota M, Yokomizo A, Uchiumi T, Kiyoshima K, Kuroiwa K, et al. Twist1 and Y-box-binding protein-1 are potential prognostic factors in bladder cancer. Urol oncol. 2014;32(1):31.e1–7. doi:10.1016/j.urolonc.2012.11.003.

    Article  CAS  Google Scholar 

  34. Shibata T, Kan H, Murakami Y, Ureshino H, Watari K, Kawahara A, et al. Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. Mol Cancer Ther. 2013;12(5):737–46. doi:10.1158/1535-7163.MCT-12-1125.

    Article  CAS  PubMed  Google Scholar 

  35. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997;3(4):447–50.

    Article  CAS  PubMed  Google Scholar 

  36. Fujiwara-Okada Y, Matsumoto Y, Fukushi J, Setsu N, Matsuura S, Kamura S, et al. Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br J Cancer. 2013;108(4):836–47. doi:10.1038/bjc.2012.579.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Woolley AG, Algie M, Samuel W, Harfoot R, Wiles A, Hung NA, et al. Prognostic association of YB-1 expression in breast cancers: a matter of antibody. PLoS ONE. 2011;6(6):e20603. doi:10.1371/journal.pone.0020603.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Szczuraszek K, Halon A, Materna V, Mazur G, Wrobel T, Kuliczkowski K, et al. Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin’s lymphomas. Anticancer Res. 2011;31(9):2963–70.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Ms. H. Isagai for technical assistance. This study was supported in part by Grants-in-Aid for Scientific Research from the Ministry for Education, Culture, Sports, Science and Technology of Japan (No. 24501323), a University of Occupational and Environmental Health Grant for Advanced Research, and the Vehicle Racing Commemorative Foundation, and a grant from the National Natural Science Foundation of China (No. 81201801).

Author information

Authors and Affiliations

  1. Department of General Practice, The First Hospital, China Medical University, Shenyang, China

    Y. Wu

  2. Shared-Use Research Center, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

    K.-Y. Wang

  3. Department of Medical Oncology, The First Hospital, China Medical University, Shenyang, China

    Z. Li & Y.-P. Liu

  4. Department of Occupational Pneumology, Institute of Industrial Ecological Science, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

    H. Izumi

  5. Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan

    S. Yamada

  6. Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan

    H. Uramoto & Y. Nakayama

  7. Department of Surgery, School of Medicine, Shinshu University, Matsumoto, Nagano, Japan

    K. Ito

  8. The President Laboratory, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan

    Y. Wu & K. Kohno

Authors
  1. Y. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K.-Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y.-P. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Izumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Uramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K. Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K. Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Kohno.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PPT 80 kb)

Supplementary material 2 (DOC 67 kb)

Supplemental Fig. Western blot for the exosome-related proteins HLA-A (Santa Cruz, USA; 1:500) and TSG101 (Santa Cruz, USA; 1:500) and YB-1 (1:5000) in cell lysis and exosomes derived from gastric cancer cell line SGC-7901. YB-1 is positive in the cancer-derived exosomes.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, Y., Wang, KY., Li, Z. et al. Y-box binding protein 1 expression in gastric cancer subtypes and association with cancer neovasculature. Clin Transl Oncol 17, 152–159 (2015). https://doi.org/10.1007/s12094-014-1208-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-014-1208-4

Keywords

Search

Navigation